MedTrace Logo

Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

NCT02062593 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2024-01-22

Study results available
· View outcomes & findings →

Summary

In this study the investigators will use careful scientific blinding of patient and their subsequent healthcare staff so that the investigators can determine exactly how much difference coronary angioplasty makes to symptoms and blood supply to the heart. After the 6 weeks blinded phase, all patients will be unblinded and the patients who had undergone sham procedure will be offered the active therapy.

Conditions

  • Stable Angina

Interventions

PROCEDURE

Coronary angioplasty

Percutaneous coronary intervention with drug-eluting stents and modern techniques

Sponsors & Collaborators

  • Volcano Corporation

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Justin E Davies, MRCP, PhD · Imperial College London

  • Darrel P Francis, MRCP, MD · Imperial College London

  • Rasha K Al-Lamee, MRCP · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-08-31
Completion
2017-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02062593 on ClinicalTrials.gov